• 1
    Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC, Brey R, Derksen R, Harris EN, Hughes GRV, Triplett DA, Khamashta MA. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999; 42: 130911.
  • 2
    Asherson RA, Cervera R, de Groot PG, Erkan D, Boffa MC, Piette JC, Khamashta MA, Shoenfeld Y. Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines. Lupus 2003; 12: 5304.
  • 3
    Crowther MA, Ginsberg JS, Julian J, Denburg J, Hirsh J, Douketis J, Laskin C, Fortin P, Anderson D, Kearon C, Clarke A, Geerts W, Forgie M, Green D, Costantini L, Yacura W, Wilson S, Gent M, Kovacs MJ. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med 2003; 349: 11338.
  • 4
    Hughes GRV. Migraine, memory loss, and ‘‘multiple sclerosis’’. Neurological features of the antiphospholipid (Hughes’) syndrome. Postgrad Med J 2003; 79: 813.
  • 5
    Letellier E, Hughes GRV. ‘‘Listen to the patient’’– anticoagulation is critical in the antiphospholipid (Hughes) syndrome. J Rheumatol 2003; 30: 897.
  • 6
    Ruiz-Irastorza G, Khamashta MA, Hunt BJ, Escudero A, Cuadrado MJ, Hughes GRV. Bleeding and recurrent thrombosis in definite antiphospholipid syndrome: analysis of a series of 66 patients treated with oral anticoagulation to a target international normalized ratio of 3.5. Arch Intern Med 2002; 162: 11649.
  • 7
    Hunt BJ, Khamashta M, Lakasing L, Williams FM, Nelson Piercy C, Bewley S, Hughes GRV. Thromboprophylaxis in antiphospholipid syndrome pregnancies with previous cerebral arterial thrombotic events: is warfarin preferable? Thromb Haemost 1998; 79: 106061.